Genentech, CDER Spar Over Third-Party Views On Avastin Breast Cancer Claim
Executive Summary
Disagreements between Genentech and FDA’s Center for Drug Evaluation and Research over the scope of evidence to be allowed at the June 28-29 hearing on Avastin’s breast cancer indication have escalated into a heated debate over the relevance of external views.